Vol 4, No 2 (2019)
Review paper
Published online: 2019-08-06

open access

Page views 1114
Article views/downloads 790
Get Citation

Connect on Social Media

Connect on Social Media

Duality nature of Selective Androgen Receptor Modulators and Specific Steroids Substance

Damian Gorczyca1, Dorota Kwiatkowska2
Disaster Emerg Med J 2019;4(2):60-62.

Abstract

Selective Androgen Receptor Modulators (SARMs) are the novel class of the androgen receptors (AR), often called tissue-selective AR ligands. Discovery of SARMs will give a possibility to the alternative therapy for androgens therapy (osteoporosis, prostate cancer, muscle wasting). SARMs should have high specificity for the AR, tissue-selective pharmacokinetic activities, improved oral bioavailability and pharmacokinetic profile which allows once-a-day administration [1].

Example of SARMs is flutamide (flutamidum, Eulexin, imid 2-methyl-N-{4-nitro-(3-trifluoromethyl)-phenyl]- propionic acid), a synthetic nonsteroidal drug that is a competitive antagonist of the androgen receptor. SARMs were recognized as forbidden substances by the World Anti-Doping Agency (WADA) and since 2004 they are on the Prohibited List. To point on the Prohibited List 2019 “Substance and methods prohibited at all time (in- and out-of-competition)” SARMs belong to group S1. 2. Other Anabolic Agents, and to group S4. Hormone Antagonist and Modulators [2].

The main role of an anti-doping laboratory is to analyse and to determine whether a given substance should be prohibited in sport. The principal analyses of SARMs and Specific Steroid Substance are a different variant of chromatography (LC — liquid or GC — gas) with many detection techniques (MS — mainly mass spectrometer, MS/MS — tandem mass spectrometer).

Article available in PDF format

View PDF Download PDF file

References

  1. Wenqing G, Dalton JT. Drug Discovery Today. 2007; 12: 241.
  2. World Anti-Doping Agency: The 2019 prohibited list, World Anti-Doping Agency, Montreal (2019). http://www.wada-ama.org/rtecontent/document/2019_List_En.pdf (14.07.2019).
  3. Macgregor JI, Jordana C. Pharmacological Reviews. 1998; 50: 151.
  4. Gjerde J, et al. Chromatogr A. 2005; 1082: 6.
  5. Thevis M., Kamber M., Schänzer W. Proceeding of the 5th Workshop on Dope analysis. Cologne, 2000.
  6. World Anti-Doping Agency: WADA annually publishes statistical reports as reported by the WADA-accredited laboratories in ADAMS, 2017 Anti-Doping Testing Figures Report - Executive Summary (online 14.07.2019).



Disaster and Emergency Medicine Journal